Pharmedix

2024

Holiday Schedule

February 19	Monday	President’s Day
May 27	Monday	Memorial Day
July 1 – July 5*	Monday-Friday	Independence   Week
September 2	Monday	Labor Day
November 28-29	Thursday-Friday	Thanksgiving   Day
December 23-31	Monday – Friday	Christmas
January 1	Wednesday	New Year’s   Holiday

Covid-19 Test Order Form 12-20

2020 Winter Closure Flyer

Pharmedix Covid‐19 Return Policy

Update 05‐05‐2020

 

Dear Valued Customer:

 

As health care providers prepare for an increase in patient visits due to COVID-19, Pharmedix has experienced a major increase in the number of units being ordered for certain prescription and OTC products. In an effort to insure that we can continue to provide product to as many clients as possible we are taking the unprecedented step of temporarily suspending our Return Policy retroactive to all orders placed on or after February 1, 2020. This means products ordered during this time period are not eligible to be returned. The only exception to this policy is in the event of a Pharmedix error in ordering and/or shipping.

 

It is our sincere hope that you will choose to order only as much product as you deem necessary for the foreseeable future. We believe this will allow your colleagues that will remain open during this crisis the opportunity to secure similar product at the time when it is most needed by their communities. You will be notified as soon as we reinstate our regular return policy.

 

Thank you for your understanding and cooperation in this matter and we look forward to continuing our successful business relationship in the months and years to come.

New FDA Requirements

Effective November 27, 2019, the FDA will be implementing new pharmaceutical traceability standards under the Drug Supply Chain Security Act (DSCSA) These new regulations will PROHIBIT all pharmaceutical distributors and wholesalers from selling pharmaceuticals below the lowest serialized unit of measure. It will be at the pharmaceutical manufacturer’s discretion to determine the lowest unit of measure they will serialize, which could be at individual “each” quantity, or at the larger box or case quantity.

This means that many items you as a client have been able to purchase by the each quantity will no longer be available at the lower unit of measure due to lack of serialization. You will still be able to order these pharmaceuticals, but they will only be available at the larger quantity, such a box or case. For example, our clients have been able to purchase single 1mL vials of epinephrine for their crash carts but now will have to purchase a box of 25 single dose vials. This will also be true for other products such as lidocaine and lidocaine with epinephrine as well as prefilled syringes for crash carts.

 

We at Pharmedix will be looking for smaller sized alternatives for our clients such as single dose epinephrine kits or boxes of 10 epinephrine ampules to replace the box of 25 epinephrine single dose vials. If you order an item which you think is a single vial unit but now only comes in a box of 10 or 25, Pharmedix customer service will contact you with pricing and/or possible alternatives. If you have any questions, please contact customer service at 1-800-486-1811 ex 14

Ranitidine Withdrawn from the Market by FDA 

 

The FDA had issued the following statement:

 

The U.S. Food and Drug Administration announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S .

 

“The FDA is committed to ensuring that the medicines Americans take are safe and effective. We make every effort to investigate potential health risks and provide our recommendations to the public based on the best available science. We didn’t observe unacceptable levels of NDMA in many of the samples that we tested. However, since we don’t know how or for how long the product might have been stored, we decided that it should not be available to consumers and patients unless its quality can be assured,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “The FDA will continue our efforts to ensure impurities in other drugs do not exceed acceptable limits so that patients can continue taking medicines without concern.”

 

We recommend that if you carry ranitidine RX or OTC that you immediately quarantine all ranitidine products. As soon as we receive notification from the various manufacturers and distributors as to how to handle this withdrawal, we will contact you as to how to dispose of the recalled product and receive credit. We have NOT received any word at this time that this recall is down to the patient level. However, if patients are concerned, they should stop taking ranitidine. If the recall is down to the patient level, they should get reimbursed by the various drug manufacturers. If you have any questions, please contact customer service at 1-800 486-1811 ex 14 or ex 17.

2020 Holiday Schedule

 

Pharmedix Online Catalog Now available.

Pharmedix Notice to Our Clients

On December 24, 2014, the FDA released guidance for the requirement under the Drug Supply Chain Security Act (DSCSA) that requires information concerning the purchase and sale of prescription pharmaceutical products to be transmitted by the manufacturer to the wholesaler and from the wholesaler to the dispenser. The Act took effect January 1, 2015, and provides for a full implementation process over a period of 10 years. The Act imposes requirements on manufacturers, wholesaler drug distributors, repackagers and dispensers to verify that all pharmaceutical products are legitimate, utilizing identification and tracing procedures as well as maintaining systems that recognize and report suspect products.

 

The enforcement date of this requirement was moved to May 1, 2015 by the FDA. The previous effective date was January 1, 2015. The guidance making this change can be found at the following link:

 

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM427867.pdf

   

As of May 1, 2015, Pharmedix is now compliant with its manufacturers and wholesale suppliers to receive and transmit data regarding the transaction history concerning the prescription products you purchase from Pharmedix™. However, depending on the vendor, prescription products purchased prior to May 1^st 2015 when DSCSA regulations took place, may have incomplete track and trace histories.  Effective July 1^st 2015, Pharmedix ™ Company will be providing access to the required Drug Supply Chain Security Act information via email and our website. The information on the website is available in a printable PDF format for a limited time.  Please contact customer service at 1-800 486-1811 to create an online account if you do not currently have access to our website.  It is your responsibility to retain this information for a period of 6 years and, if necessary, transmit the required information to your down-stream customers as required by the Drug Supply Chain Security Act.

Pharmedix™ will continue to supply pedigrees to states that require pedigree papers (where pedigrees are still available) until May 1^st 2015, even though this new legislation supersedes any and all state pedigree requirements.

Google Chrome web browser is not compatible to Pharmedix Online Catalog at this time. Please use Internet Explorer or Firefox.